Compare NVEC & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | RZLT |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.4M | 321.6M |
| IPO Year | 1995 | 2011 |
| Metric | NVEC | RZLT |
|---|---|---|
| Price | $90.56 | $3.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 112.0K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | 0.96 | ★ 26.32 |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $26,331,218.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.92 | ★ N/A |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $57.21 | $1.07 |
| 52 Week High | $110.03 | $11.46 |
| Indicator | NVEC | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 49.88 |
| Support Level | $63.38 | $2.93 |
| Resistance Level | $110.03 | $3.60 |
| Average True Range (ATR) | 6.85 | 0.21 |
| MACD | -0.63 | -0.00 |
| Stochastic Oscillator | 45.88 | 56.90 |
NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.